A novel interaction of CLN3 with nonmuscle myosin-IIB and defects in cell motility of Cln3-/- cells

Experimental Cell Research

Volumn 317, Issue 1, 2011, Pages 51-69

  Getty, Amanda L ^a   Benedict, Jared W ^a   Pearce, David A ^a,b,c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b SANFORD RESEARCH   (United States)

^c UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Batten disease; Motility; Neurodegeneration; Scratch assay

Indexed keywords

BETA CATENIN; BLEBBISTATIN; CALBINDIN; CELL MARKER; CEROID NEURONAL LIPOFUSCINOSIS TYPE 3 PROTEIN; CHLOROQUINE; MEMBRANE PROTEIN; MESSENGER RNA; MYOSIN IIB; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL JUNCTION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL ULTRASTRUCTURE; CELL VIABILITY; CEREBELLUM; CONTROLLED STUDY; EMBRYO; FIBROBLAST CULTURE; GENE EXPRESSION; GENOTYPE PHENOTYPE CORRELATION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; KNOCKOUT MOUSE; LYSOSOME; MOUSE; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TWO HYBRID SYSTEM;

MUS;

EID: 78449274362     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.09.007     Document Type: Article

References (81)

1. Goebel H.H. The neuronal ceroid-lipofuscinoses. J. Child Neurol. 1995, 10:424-437.
2. Consortium B.D. Isolation of a novel gene underlying Batten disease, CLN3. The International Batten Disease Consortium. Cell 1995, 82:949-957.
3. Mole S.E. NCL Mutation Database http://www.ucl.ac.uk/ncl/mutation.shtml.
4. Pontikis C.C., Cotman S.L., MacDonald M.E., Cooper J.D. Thalamocortical neuron loss and localized astrocytosis in the Cln3Deltaex7/8 knock-in mouse model of Batten disease. Neurobiol. Dis. 2005, 20:823-836.
5. Pontikis C.C., Cella C.V., Parihar N., Lim M.J., Chakrabarti S., Mitchison H.M., Mobley W.C., Rezaie P., Pearce D.A., Cooper J.D. Late onset neurodegeneration in the Cln3-/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res. 2004, 1023:231-242.
6. Weimer J.M., Custer A.W., Benedict J.W., Alexander N.A., Kingsley E., Federoff H.J., Cooper J.D., Pearce D.A. Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons. Neurobiol. Dis. 2006, 22:284-293.
7. Weimer J.M., Benedict J.W., Getty A.L., Pontikis C.C., Lim M.J., Cooper J.D., Pearce D.A. Cerebellar defects in a mouse model of juvenile neuronal ceroid lipofuscinosis. Brain Res. 2009, 1266:93-107.
8. Luiro K., Yliannala K., Ahtiainen L., Maunu H., Jarvela I., Kyttala A., Jalanko A. Interconnections of CLN3, Hook1 and Rab proteins link Batten disease to defects in the endocytic pathway. Hum. Mol. Genet. 2004, 13:3017-3027.
9. Ramirez-Montealegre D., Pearce D.A. Defective lysosomal arginine transport in juvenile Batten disease. Hum. Mol. Genet. 2005, 14:3759-3773.
10. Kyttala A., Yliannala K., Schu P., Jalanko A., Luzio J.P. AP-1 and AP-3 facilitate lysosomal targeting of Batten disease protein CLN3 via its dileucine motif. J. Biol. Chem. 2005, 280:10277-10283.
11. Phillips S.N., Benedict J.W., Weimer J.M., Pearce D.A. CLN3, the protein associated with batten disease: structure, function and localization. J. Neurosci. Res. 2005, 79:573-583.
12. Chang J.W., Choi H., Kim H.J., Jo D.G., Jeon Y.J., Noh J.Y., Park W.J., Jung Y.K. Neuronal vulnerability of CLN3 deletion to calcium-induced cytotoxicity is mediated by calsenilin. Hum. Mol. Genet. 2007, 16:317-326.
13. Uusi-Rauva K., Luiro K., Tanhuanpaa K., Kopra O., Martin-Vasallo P., Kyttala A., Jalanko A. Novel interactions of CLN3 protein link Batten disease to dysregulation of fodrin-Na+, K+ ATPase complex. Exp. Cell Res. 2008, 314:2895-2905.
14. Vitiello S.P., Benedict J.W., Padilla-Lopez S., Pearce D.A. Interaction between Sdo1p and Btn1p in the Saccharomyces cerevisiae model for Batten disease. Hum. Mol. Genet. 2010, 19:931-942.
15. Takeda K., Kishi H., Ma X., Yu Z.X., Adelstein R.S. Ablation and mutation of nonmuscle myosin heavy chain II-B results in a defect in cardiac myocyte cytokinesis. Circ. Res. 2003, 93:330-337.
16. Lo C.M., Buxton D.B., Chua G.C., Dembo M., Adelstein R.S., Wang Y.L. Nonmuscle myosin IIb is involved in the guidance of fibroblast migration. Mol. Biol. Cell 2004, 15:982-989.
17. Vicente-Manzanares M., Koach M.A., Whitmore L., Lamers M.L., Horwitz A.F. Segregation and activation of myosin IIB creates a rear in migrating cells. J. Cell Biol. 2008, 183:543-554.
18. Vicente-Manzanares M., Zareno J., Whitmore L., Choi C.K., Horwitz A.F. Regulation of protrusion, adhesion dynamics, and polarity by myosins IIA and IIB in migrating cells. J. Cell Biol. 2007, 176:573-580.
19. Wylie S.R., Chantler P.D. Separate but linked functions of conventional myosins modulate adhesion and neurite outgrowth. Nat. Cell Biol. 2001, 3:88-92.
20. Heath K.E., Campos-Barros A., Toren A., Rozenfeld-Granot G., Carlsson L.E., Savige J., Denison J.C., Gregory M.C., White J.G., Barker D.F., Greinacher A., Epstein C.J., Glucksman M.J., Martignetti J.A. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am. J. Hum. Genet. 2001, 69:1033-1045.
21. Marqueze-Pouey B., Martin-Moutot N., Sakkou-Norton M., Leveque C., Ji Y., Cornet V., Hsiao W.L., Seagar M. Toxicity and endocytosis of spinocerebellar ataxia type 6 polyglutamine domains: role of myosin IIb. Traffic 2008, 9:1088-1100.
22. Ryu J., Liu L., Wong T.P., Wu D.C., Burette A., Weinberg R., Wang Y.T., Sheng M. A critical role for myosin IIb in dendritic spine morphology and synaptic function. Neuron 2006, 49:175-182.
23. Bridgman P.C., Dave S., Asnes C.F., Tullio A.N., Adelstein R.S. Myosin IIB is required for growth cone motility. J. Neurosci. 2001, 21:6159-6169.
24. Takagishi Y., Futaki S., Itoh K., Espreafico E.M., Murakami N., Murata Y., Mochida S. Localization of myosin II and V isoforms in cultured rat sympathetic neurones and their potential involvement in presynaptic function. J. Physiol. 2005, 569:195-208.
25. Conti M.A., Adelstein R.S. Nonmuscle myosin II moves in new directions. J. Cell Sci. 2008, 121:11-18.
26. Seehafer S.S., Pearce D.A. Spectral properties and mechanisms that underlie autofluorescent accumulations in Batten disease. Biochem. Biophys. Res. Commun. 2009, 382:247-251.
27. Rosenberger G., Gal A., Kutsche K. AlphaPIX associates with calpain 4, the small subunit of calpain, and has a dual role in integrin-mediated cell spreading. J. Biol. Chem. 2005, 280:6879-6889.
28. Cottone C.D., Chattopadhyay S., Pearce D.A. Searching for interacting partners of CLN1, CLN2 and Btn1p with the two-hybrid system. Eur J Paediatr Neurol 2001, 5(Suppl A):95-98.
29. Weimer J.M., Chattopadhyay S., Custer A.W., Pearce D.A. Elevation of Hook1 in a disease model of Batten disease does not affect a novel interaction between Ankyrin G and Hook1. Biochem. Biophys. Res. Commun. 2005, 330:1176-1181.
30. Mitchison H.M., Bernard D.J., Greene N.D., Cooper J.D., Junaid M.A., Pullarkat R.K., de Vos N., Breuning M.H., Owens J.W., Mobley W.C., Gardiner R.M., Lake B.D., Taschner P.E., Nussbaum R.L. Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium [corrected]. Neurobiol. Dis. 1999, 6:321-334.
31. Chan C.H., Mitchison H.M., Pearce D.A. Transcript and in silico analysis of CLN3 in juvenile neuronal ceroid lipofuscinosis and associated mouse models. Hum. Mol. Genet. 2008, 17:3332-3339.
32. Elshatory Y., Brooks A.I., Chattopadhyay S., Curran T.M., Gupta P., Ramalingam V., Hofmann S.L., Pearce D.A. Early changes in gene expression in two models of Batten disease. FEBS Lett. 2003, 538:207-212.
33. Weimer J.M., Benedict J.W., Elshatory Y.M., Short D.W., Ramirez-Montealegre D., Ryan D.A., Alexander N.A., Federoff H.J., Cooper J.D., Pearce D.A. Alterations in striatal dopamine catabolism precede loss of substantia nigra neurons in a mouse model of juvenile neuronal ceroid lipofuscinosis. Brain Res. 2007, 1162:98-112.
34. Kovacs A.D., Weimer J.M., Pearce D.A. Selectively increased sensitivity of cerebellar granule cells to AMPA receptor-mediated excitotoxicity in a mouse model of Batten disease. Neurobiol. Dis. 2006, 22:575-585.
35. Quilliam L.A., Huff S.Y., Rabun K.M., Wei W., Park W., Broek D., Der C.J. Membrane-targeting potentiates guanine nucleotide exchange factor CDC25 and SOS1 activation of Ras transforming activity. Proc. Natl. Acad. Sci. USA 1994, 91:8512-8516.
36. Ezaki J., Takeda-Ezaki M., Koike M., Ohsawa Y., Taka H., Mineki R., Murayama K., Uchiyama Y., Ueno T., Kominami E. Characterization of Cln3p, the gene product responsible for juvenile neuronal ceroid lipofuscinosis, as a lysosomal integral membrane glycoprotein. J. Neurochem. 2003, 87:1296-1308.
37. Kyttala A., Ihrke G., Vesa J., Schell M.J., Luzio J.P. Two motifs target Batten disease protein CLN3 to lysosomes in transfected nonneuronal and neuronal cells. Mol. Biol. Cell 2004, 15:1313-1323.
38. Swailes N.T., Colegrave M., Knight P.J., Peckham M. Non-muscle myosins 2A and 2B drive changes in cell morphology that occur as myoblasts align and fuse. J. Cell Sci. 2006, 119:3561-3570.
39. Vicente-Manzanares M., Ma X., Adelstein R.S., Horwitz A.R. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat. Rev. Mol. Cell Biol. 2009, 10:778-790.
40. Beadle C., Assanah M.C., Monzo P., Vallee R., Rosenfeld S.S., Canoll P. The role of myosin II in glioma invasion of the brain. Mol. Biol. Cell 2008, 19:3357-3368.
41. Bindschadler M., McGrath J.L. Sheet migration by wounded monolayers as an emergent property of single-cell dynamics. J. Cell Sci. 2007, 120:876-884.
42. Gage F.H. Mammalian neural stem cells. Science 2000, 287:1433-1438.
43. Allingham J.S., Smith R., Rayment I. The structural basis of blebbistatin inhibition and specificity for myosin II. Nat. Struct. Mol. Biol. 2005, 12:378-379.
44. Song J.W., Misgeld T., Kang H., Knecht S., Lu J., Cao Y., Cotman S.L., Bishop D.L., Lichtman J.W. Lysosomal activity associated with developmental axon pruning. J. Neurosci. 2008, 28:8993-9001.
45. Metcalf D.J., Calvi A.A., Seaman M., Mitchison H.M., Cutler D.F. Loss of the Batten disease gene CLN3 prevents exit from the TGN of the mannose 6-phosphate receptor. Traffic 2008, 9:1905-1914.
46. Pohl S., Mitchison H.M., Kohlschutter A., van Diggelen O., Braulke T., Storch S. Increased expression of lysosomal acid phosphatase in CLN3-defective cells and mouse brain tissue. J. Neurochem. 2007, 103:2177-2188.
47. Michihara A., Toda K., Kubo T., Fujiwara Y., Akasaki K., Tsuji H. Disruptive effect of chloroquine on lysosomes in cultured rat hepatocytes. Biol. Pharm. Bull. 2005, 28:947-951.
48. Gonzalez-Noriega A., Grubb J.H., Talkad V., Sly W.S. Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling. J. Cell Biol. 1980, 85:839-852.
49. Pearce D.A., Nosel S.A., Sherman F. Studies of pH regulation by Btn1p, the yeast homolog of human Cln3p. Mol. Genet. Metab. 1999, 66:320-323.
50. Golabek A.A., Kida E., Walus M., Kaczmarski W., Michalewski M., Wisniewski K.E. CLN3 protein regulates lysosomal pH and alters intracellular processing of Alzheimer's amyloid-beta protein precursor and cathepsin D in human cells. Mol. Genet. Metab. 2000, 70:203-213.
51. Holopainen J.M., Saarikoski J., Kinnunen P.K., Jarvela I. Elevated lysosomal pH in neuronal ceroid lipofuscinoses. Eur. J. Biochem. 2001, 268:5851-5856.
52. Padilla-Lopez S., Pearce D.A. Saccharomyces cerevisiae lacking Btn1p modulate vacuolar ATPase activity to regulate pH imbalance in the vacuole. J. Biol. Chem. 2006, 281:10273-10280.
53. Codlin S., Haines R.L., Burden J.J., Mole S.E. Btn1 affects cytokinesis and cell-wall deposition by independent mechanisms, one of which is linked to dysregulation of vacuole pH. J. Cell Sci. 2008, 121:2860-2870.
54. Cao Y., Espinola J.A., Fossale E., Massey A.C., Cuervo A.M., MacDonald M.E., Cotman S.L. Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. J. Biol. Chem. 2006, 281:20483-20493.
55. Bottger B.A., Sjolund M., Thyberg J. Chloroquine and monensin inhibit induction of DNA synthesis in rat arterial smooth muscle cells stimulated with platelet-derived growth factor. Cell Tissue Res. 1988, 252:275-285.
56. Codlin S., Haines R.L., Mole S.E. btn1 affects endocytosis, polarization of sterol-rich membrane domains and polarized growth in Schizosaccharomyces pombe. Traffic 2008, 9:936-950.
57. Togo T., Steinhardt R.A. Nonmuscle myosin IIA and IIB have distinct functions in the exocytosis-dependent process of cell membrane repair. Mol. Biol. Cell 2004, 15:688-695.
58. Kolega J. Asymmetric distribution of myosin IIB in migrating endothelial cells is regulated by a rho-dependent kinase and contributes to tail retraction. Mol. Biol. Cell 2003, 14:4745-4757.
59. Zhang M., Rao P.V. Blebbistatin, a novel inhibitor of myosin II ATPase activity, increases aqueous humor outflow facility in perfused enucleated porcine eyes. Invest. Ophthalmol. Vis. Sci. 2005, 46:4130-4138.
60. Tullio A.N., Accili D., Ferrans V.J., Yu Z.X., Takeda K., Grinberg A., Westphal H., Preston Y.A., Adelstein R.S. Nonmuscle myosin II-B is required for normal development of the mouse heart. Proc. Natl. Acad. Sci. USA 1997, 94:12407-12412.
61. Ma X., Bao J., Adelstein R.S. Loss of cell adhesion causes hydrocephalus in nonmuscle myosin II-B-ablated and mutated mice. Mol. Biol. Cell 2007, 18:2305-2312.
62. Miyazaki T., Watanabe M., Yamagishi A., Takahashi M. B2 exon splicing of nonmuscle myosin heavy chain IIB is differently regulated in developing and adult rat brain. Neurosci. Res. 2000, 37:299-306.
63. Murakami N., Trenkner E., Elzinga M. Changes in expression of nonmuscle myosin heavy chain isoforms during muscle and nonmuscle tissue development. Dev. Biol. 1993, 157:19-27.
64. Ma X., Kawamoto S., Hara Y., Adelstein R.S. A point mutation in the motor domain of nonmuscle myosin II-B impairs migration of distinct groups of neurons. Mol. Biol. Cell 2004, 15:2568-2579.
65. Ma X., Kawamoto S., Uribe J., Adelstein R.S. Function of the neuron-specific alternatively spliced isoforms of nonmuscle myosin II-B during mouse brain development. Mol. Biol. Cell 2006, 17:2138-2149.
66. Belly A., Bodon G., Blot B., Bouron A., Sadoul R., Goldberg Y. CHMP2B mutants linked to frontotemporal dementia impair maturation of dendritic spines. J. Cell Sci. 2010, 123(Pt 17):2943-2954.
67. Ishmael J.E., Safic M., Amparan D., Vogel W.K., Pham T., Marley K., Filtz T.M., Maier C.S. Nonmuscle myosins II-B and Va are components of detergent-resistant membrane skeletons derived from mouse forebrain. Brain Res. 2007, 1143:46-59.
68. Rakheja D., Narayan S.B., Pastor J.V., Bennett M.J. CLN3P, the Batten disease protein, localizes to membrane lipid rafts (detergent-resistant membranes). Biochem. Biophys. Res. Commun. 2004, 317:988-991.
69. Hering H., Lin C.C., Sheng M. Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J. Neurosci. 2003, 23:3262-3271.
70. Prasad V.V., Pullarkat R.K. Brain lysosomal hydrolases in neuronal ceroid-lipofuscinoses. Mol. Chem. Neuropathol. 2010, 123(Pt 6):169-179.
71. Sleat D.E., Sohar I., Pullarkat P.S., Lobel P., Pullarkat R.K. Specific alterations in levels of mannose 6-phosphorylated glycoproteins in different neuronal ceroid lipofuscinoses. Biochem. J. 1998, 334(Pt 3):547-551.
72. Stein C.S., Yancey P.H., Martins I., Sigmund R.D., Stokes J.B., Davidson B.L. Osmoregulation of ceroid neuronal lipofuscinosis type 3 (CLN3) in the renal medulla. Am. J. Physiol. Cell Physiol. 2010, 298(6):C1388-C1400.
73. Hobert J.A., Dawson G. A novel role of the Batten disease gene CLN3: association with BMP synthesis. Biochem. Biophys. Res. Commun. 2007, 358:111-116.
74. Rusyn E., Mousallem T., Persaud-Sawin D.A., Miller S., Boustany R.M. CLN3p impacts galactosylceramide transport, raft morphology, and lipid content. Pediatr. Res. 2008, 63:625-631.
75. Ramirez-Montealegre D., Chattopadhyay S., Curran T.M., Wasserfall C., Pritchard L., Schatz D., Petitto J., Hopkins D., She J.X., Rothberg P.G., Atkinson M., Pearce D.A. Autoimmunity to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Neurology 2005, 64:743-745.
76. Chan C.H., Ramirez-Montealegre D., Pearce D.A. Altered arginine metabolism in the central nervous system (CNS) of the Cln3-/- mouse model of juvenile Batten disease. Neuropathol. Appl. Neurobiol. 2009, 35:189-207.
77. Pearce D.A., Ferea T., Nosel S.A., Das B., Sherman F. Action of BTN1, the yeast orthologue of the gene mutated in Batten disease. Nat. Genet. 1999, 22:55-58.
78. Pearce D.A., Carr C.J., Das B., Sherman F. Phenotypic reversal of the btn1 defects in yeast by chloroquine: a yeast model for Batten disease. Proc. Natl. Acad. Sci. USA 1999, 96:11341-11345.
79. Persaud-Sawin D.A., VanDongen A., Boustany R.M. Motifs within the CLN3 protein: modulation of cell growth rates and apoptosis. Hum. Mol. Genet. 2002, 11:2129-2142.
80. Puranam K.L., Guo W.X., Qian W.H., Nikbakht K., Boustany R.M. CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide. Mol. Genet. Metab. 1999, 66:294-308.
81. Persaud-Sawin D.A., McNamara J.O., Rylova S., Vandongen A., Boustany R.M. A galactosylceramide binding domain is involved in trafficking of CLN3 from Golgi to rafts via recycling endosomes. Pediatr. Res. 2004, 56:449-463.